DSM-Firmenich AG (DSFIY)
The price, the headline numbers and the latest news, in one place.
DSM-Firmenich AG (DSFIY) Stock Price, Analysis & Data
No data available
| Bid | 10.94 |
| Market Cap | 27B |
| Revenue (ttm) | 9.05B |
| Net Income (ttm) | 324M |
| 0.56 | |
| 0.16 | |
| 68.56 | |
| 22.54 | |
| P/B (ttm) | 1.33 |
| P/S (ttm) | 2.98 |
| Earnings Date | n/a |
| Ask | 10.97 |
| Volume | 66,799 |
| Avg. Volume (20D) | 290,980 |
| Open | 11.05 |
| Previous Close | 10.85 |
| Day's Range | 10.90 - 11.05 |
| 52-Week Range | 6.40 - 11.14 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $2.00 (18.31%) |
| Ex-Dividend Date | May 12, 2026 |
About DSFIY
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food ...
Financial Performance
In 2025, DSM-Firmenich's revenue was 9.03B, a decrease of -0.22% compared to the previous year's 9.05B. Earnings were -1.08B, a decrease of -532.4%.
Financial StatementsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
3 months ago · Simply Wall St.
DSM-Firmenich Medisca Deal Highlights U.S. Vitamin API And Valuation UpsideDSM-Firmenich (ENXTAM:DSFIR) has partnered with Medisca to expand access to pharmaceutical-grade vitamin active pharmaceutical ingredients in the U.S. market. The agreement focuses on supplying Europe...